NCT04853719View on ClinicalTrials.gov

Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions
Peripheral Artery DiseaseIntermittent Claudication
Interventions
DRUG

Rivaroxaban 2.5 Mg Oral Tablet

oral anticoagulants plus antiplatelet agent

Trial Locations (2)

09030-010

Hospital e Maternidade Christovão da Gama - Science Valley clinical site, Santo André

09030370

Science Valley Research Institute, Santo André

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Science Valley Research Institute

OTHER

NCT04853719 - Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients | Biotech Hunter | Biotech Hunter